Oridonin inhibits cancer cells invasion and metastasis through targeting various transcription factors and their signaling pathways such as TGF-β1 [70], EGFR [60], mammalian target of rapamycin (mTOR) [71], long non-coding RNAs (lncRNAs) [53] as well as increasing the activity of tumor suppressor genes (i.e., p53 and protein phosphatase 2A (PP2A)) [72]. The gene discussed is MTOR; the disease is cancer.